logo
  

ANI Pharma Q1 Profit Tops Estimates

ANI Pharmaceuticals, Inc. (ANIP) reported first quarter adjusted non-GAAP earnings per share of $1.04, flat with prior year. On average, three analysts polled by Thomson Reuters expected the company to report profit per share of $0.71, for the quarter. Analysts' estimates typically exclude special items. GAAP net income was $0.1 million, and GAAP earnings per share was $0.01, for the quarter.

First quarter net revenues were $54.5 million compared to $49.8 million, last year. Analysts expected revenue of $46.8 million, for the quarter.

Cash and cash equivalents were $25.1 million, net accounts receivable was $91.9 million, as of March 31, 2021.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Mallinckrodt plc announced Wednesday that the U.S. Food and Drug Administration or FDA has approved StrataGraft (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen - dsat) for the treatment of adult patients with thermal burns containing intact dermal elements for which surgical intervention is clinically indicated. Worldwide 5G mobile subscriptions are estimated to exceed 580 million by the end of 2021, according to the Ericsson Mobility Report. With subscriptions increasing at a rate of about a million per day, 5G remains on track to become the fastest adopted mobile generation in history. The growth in subscriptions is being lead by China, North America and the Gulf Cooperation Council markets. Elanco Animal Health Inc. (ELAN) and veterinary biopharmaceutical company Kindred Biosciences, Inc. (KIN) announced Wednesday they have entered into a definitive agreement for Elanco to acquire Kindred for $9.25 per share, or approximately $440 million. The acquisition further accelerates Elanco's...
RELATED NEWS
Follow RTT